A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Boehringer Ingelheim
Atavistik Bio, Inc
Zhejiang University
West China Hospital
Eisai Inc.
Daiichi Sankyo
Replimune Inc.
Pfizer
Werewolf Therapeutics, Inc.
Baylor College of Medicine
ModernaTX, Inc.
Children's Hospital Los Angeles
EMD Serono
M.D. Anderson Cancer Center
GlaxoSmithKline
AgonOx, Inc.
UNC Lineberger Comprehensive Cancer Center
Novartis
AbbVie
Bristol-Myers Squibb
Baylor College of Medicine
Amgen
AstraZeneca
AstraZeneca
Tesaro, Inc.
M.D. Anderson Cancer Center
AbbVie
Vividion Therapeutics, Inc.
M.D. Anderson Cancer Center
Turning Point Therapeutics, Inc.
HUYABIO International, LLC.
HUYABIO International, LLC.
Albert Einstein College of Medicine
DeuterOncology
Exelixis
AbbVie
AbbVie
iTeos Therapeutics
AbbVie
Nuvectis Pharma, Inc.
AbbVie
AbbVie
AbbVie
Shanghai Henlius Biotech
AbbVie
West China Hospital
DEKA Biosciences
AbbVie
UNC Lineberger Comprehensive Cancer Center
Genmab